Victory Capital Management Inc. Decreases Stock Position in Dynavax Technologies Co. (NASDAQ:DVAX)

Victory Capital Management Inc. lowered its stake in shares of Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 15.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 169,730 shares of the biopharmaceutical company's stock after selling 31,576 shares during the period. Victory Capital Management Inc. owned 0.13% of Dynavax Technologies worth $2,167,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the stock. US Bancorp DE lifted its holdings in Dynavax Technologies by 291.4% during the 3rd quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company's stock worth $30,000 after purchasing an additional 2,034 shares in the last quarter. Smartleaf Asset Management LLC lifted its holdings in shares of Dynavax Technologies by 463.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 2,473 shares of the biopharmaceutical company's stock worth $32,000 after buying an additional 2,034 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of Dynavax Technologies by 55.1% in the fourth quarter. GAMMA Investing LLC now owns 4,102 shares of the biopharmaceutical company's stock valued at $52,000 after acquiring an additional 1,457 shares during the period. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new position in shares of Dynavax Technologies in the fourth quarter valued at approximately $71,000. Finally, Nisa Investment Advisors LLC grew its stake in Dynavax Technologies by 19.8% during the fourth quarter. Nisa Investment Advisors LLC now owns 6,517 shares of the biopharmaceutical company's stock valued at $83,000 after acquiring an additional 1,076 shares in the last quarter. 96.96% of the stock is owned by institutional investors.

Remove Ads

Dynavax Technologies Price Performance

NASDAQ DVAX traded up $0.20 during trading hours on Friday, reaching $13.82. 1,152,740 shares of the stock traded hands, compared to its average volume of 1,991,391. The stock has a 50 day simple moving average of $13.19 and a two-hundred day simple moving average of $12.37. Dynavax Technologies Co. has a 1 year low of $9.74 and a 1 year high of $14.63. The company has a debt-to-equity ratio of 0.33, a current ratio of 13.23 and a quick ratio of 12.34. The company has a market cap of $1.71 billion, a price-to-earnings ratio of 76.75 and a beta of 1.23.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last released its earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share for the quarter, hitting analysts' consensus estimates of $0.05. Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%. The company had revenue of $72.03 million during the quarter, compared to the consensus estimate of $72.70 million. On average, analysts predict that Dynavax Technologies Co. will post 0.32 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have commented on DVAX shares. William Blair reissued an "outperform" rating on shares of Dynavax Technologies in a report on Friday, February 21st. StockNews.com upgraded Dynavax Technologies from a "hold" rating to a "buy" rating in a research note on Monday, February 24th. The Goldman Sachs Group downgraded Dynavax Technologies from a "neutral" rating to a "sell" rating and dropped their price target for the company from $15.00 to $12.00 in a research report on Tuesday, February 11th. Finally, HC Wainwright restated a "buy" rating and issued a $31.00 price objective on shares of Dynavax Technologies in a research report on Friday, February 21st.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.